Doxycycline in Combination With Sitagliptin on the Glycemic and Cardiac Indices in Patients With Type 2 Diabetes Mellitus
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia, weight loss, and cardio-metabolic complications. T2DM develops due to the progression of insulin resistance (IR), impairment of insulin insensitivity, and failure of the pancreatic β-cells to release sufficient amount of insulin in response to glucose burden
Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Maximum Age: 60
Healthy Volunteers: f
View:
• Male or female sex more than 40 years old Newly diagnosed type II diabetes. HbA1c more than 6.5
Locations
Other Locations
Egypt
Tanta Unuversity
RECRUITING
Tanta
Time Frame
Start Date: 2024-03-30
Estimated Completion Date: 2026-04-20
Participants
Target number of participants: 60
Treatments
Active_comparator: control group
patients were on sitagliptin 100mg /day monotherapy
Active_comparator: Comparative group
patients were on sitagliptin 100mg /day monotherapy plus doxycycline 100 mg
Related Therapeutic Areas
Sponsors
Leads: Mostafa Bahaa